Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)

• Joachim G J V Aerts,
• Sjoerd H van der Burg,
• Martijn P Lolkema,
• Sai Ping Lau,
• Freek R van ’t Land,
• Marjolein Y V Homs,
• Casper H J van Eijck

Affiliations

Joachim G J V Aerts

Pulmonary Medicine, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands

Sjoerd H van der Burg

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Martijn P Lolkema

Department of Medical Oncology, Erasmus Medical Center Cancer Center. Erasmus Medical Center, Rotterdam, The Netherlands

Sai Ping Lau

Department of Surgery, Erasmus MC, Rotterdam, The Netherlands

Freek R van ’t Land

Department of Surgery, Erasmus MC, Rotterdam, The Netherlands

Marjolein Y V Homs

Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands

Casper H J van Eijck

Department of Surgery, Erasmus MC, Rotterdam, The Netherlands